Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I
PublisherNature Publishing Group
MetadataShow full item record
AbstractLysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can improve biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. These studies provide support for the development of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes making it applicable to other lysosomal storage disorders. Copyright 2019, The Author(s).
SponsorsThis work was supported by the Stanford's Child Health Research Institute (CHRI), the National Organization of Rare Disorders (NORD), the Thrasher Research Fund, the National Institute of Neurological Disorders and Stroke (NINDS, 1K08NS102398-01 to N.G-O), and in part by the Cancer Prevention and Research Institute of Texas (RR140081 and RR170721 to G.B.).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85071896825&doi=10.1038%2fs41467-019-11962-8&partnerID=40&md5=cd1f9923ad62048338cc2dbfeeee8a84; http://hdl.handle.net/10713/10897
- CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
- Authors: Xu L, Yang H, Gao Y, Chen Z, Xie L, Liu Y, Liu Y, Wang X, Li H, Lai W, He Y, Yao A, Ma L, Shao Y, Zhang B, Wang C, Chen H, Deng H
- Issue date: 2017 Aug 2
- CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts.
- Authors: de Carvalho TG, Schuh R, Pasqualim G, Pellenz FM, Filippi-Chiela EC, Giugliani R, Baldo G, Matte U
- Issue date: 2018 Dec 15
- Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.
- Authors: Dai M, Han J, El-Amouri SS, Brady RO, Pan D
- Issue date: 2014 Feb 18
- Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
- Authors: Park SH, Lee CM, Dever DP, Davis TH, Camarena J, Srifa W, Zhang Y, Paikari A, Chang AK, Porteus MH, Sheehan VA, Bao G
- Issue date: 2019 Sep 5
- CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
- Authors: Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH
- Issue date: 2016 Nov 17